Highlights

  • CONNEQT Health (ASX:CQT) reported FY26 revenue of AUD 6.30 million, up from AUD 3.55 million.
  • The statutory net loss narrowed to AUD 10.86 million from AUD 18.19 million.
  • Clinical subscription sites increased from two to 17 by 30 June 2026.
  • Year-end cash reached AUD 2.57 million, while the annual report identified funding uncertainty.

CONNEQT Health Limited (ASX:CQT) develops cardiovascular monitoring devices and related digital services for consumers, healthcare providers and researchers. The company’s FY26 results show increased sales from its arterial health technology, alongside continuing operating losses and a need to manage funding. Its recent US distribution agreement and expansion of clinical subscriptions add context to the financial results. At the time of writing this article on 19 October 2026, CONNEQT Health Limited (ASX:CQT) shares were trading at AUD 0.011, up 10.00% during the day’s trading session.

Company Business

The Sydney-based company designs and markets medical and home monitoring products built around its SphygmoCor vascular biomarker technology. Its systems measure aspects of arterial function, including central blood pressure and arterial stiffness. The business serves pharmaceutical research, academic institutions, clinical users and consumers, with activities across international markets.

CONNEQT Pulse is its consumer arterial health monitor, accompanied by the CONNEQT app and paid digital offerings such as Care+ and Cardiology Reports. For professional users, the company supplies established SphygmoCor systems and is developing enterprise subscriptions and software-based delivery. These businesses have different purchasing patterns: research contracts depend partly on study activity and budgets, while consumer revenue depends on device sales and repeat digital engagement.

Recent Development

In September 2026, CONNEQT agreed with US preventive-health platform Blueprint to offer Pulse through its Protocol Marketplace. The arrangement adds a consumer distribution channel, although the annual report did not provide guaranteed sales volumes or contract revenue. Commercial results will depend on purchases made through that channel rather than the agreement alone.

The company also reported progress in enterprise subscriptions. Initial clinical pilots became two-year commercial agreements during the December 2025 quarter, and subscribed clinical sites increased from two to 17 by the end of June 2026. Management is developing SphygmoCor Cloud and submitted an FDA pre-submission during the June quarter, with a regulatory clearance application targeted for mid-FY27. Submission and regulatory review remain separate from a completed clearance.

Following a September extraordinary general meeting, the company issued shares for a second placement tranche and in settlement of director-related loans. These transactions changed its post-year-end capital structure and helped address part of the liabilities shown in its June balance sheet.

Financial Performance and Sector Context

For the year ended 30 June 2026, statutory revenue was AUD 6.30 million compared with AUD 3.55 million in FY25, an increase of approximately 77%. Gross profit rose to AUD 4.56 million from AUD 2.56 million. Other income was AUD 1.66 million, down from AUD 2.55 million. The net loss narrowed to AUD 10.86 million from AUD 18.19 million, with total expenses declining to AUD 17.10 million from AUD 23.30 million.

Customer receipts increased to AUD 5.65 million from AUD 3.43 million, while net operating cash outflow declined to AUD 9.71 million from AUD 10.90 million. Cash and equivalents stood at AUD 2.57 million at 30 June 2026, against AUD 2.43 million a year earlier. Current liabilities of AUD 8.90 million exceeded current assets of AUD 7.17 million at year-end.

The company operates in regulated medical technology, where device authorisations, production reliability, research spending and clinical adoption shape commercial activity. Its consumer and enterprise initiatives introduce subscription models, but device production and customer acquisition also require working capital ahead of receipts.

Risks to Consider

The FY26 financial statements identified a material uncertainty that may cast significant doubt on the group’s ability to continue as a going concern. The auditor drew attention to this matter without modifying its opinion. Other disclosed risks include continued cash expenditure, access to additional capital, inventory management, component availability, regulatory approvals and demand for newer products. Equity financing can also change the number of shares on issue.

What to Watch Next

Relevant developments include Pulse device sales and repeat digital subscriptions, additional clinical-site agreements, the proposed SphygmoCor Cloud regulatory application, quarterly customer receipts and operating cash flow. Subsequent funding transactions and progress in converting product adoption into recurring revenue will also affect interpretation of the company’s financial position.

Key Insights

CONNEQT’s FY26 results combined higher revenue and a reduced statutory loss with continuing cash outflows and a year-end net liability position. The US distribution agreement and clinical subscription growth extend its commercial activity, while funding requirements and regulatory milestones remain material factors to monitor.